医学
子宫内膜癌
内科学
肿瘤科
放射治疗
阶段(地层学)
辅助治疗
佐剂
存活率
妇科
癌症
古生物学
生物
作者
Utku Akgör,Derman Başaran,Mehmet Mutlu Meydanlı,Esra Kuşçu,Fuat Demirkıran,Samet Topuz,Muzaffer Şancı,Özgür Akbayır,Murat Gultekın,Mehmet Yavuz Salihoğlu,Hüseyin Akıllı,Tugan Beşe,Zeliha Fırat,Hamdullah Sözen,Nejat Ozgul,Ali Ayhan
出处
期刊:International Journal of Gynecological Cancer
[BMJ]
日期:2024-06-05
卷期号:: ijgc-005368
标识
DOI:10.1136/ijgc-2024-005368
摘要
Objective The aim of this study was to investigate the impact of adjuvant treatments, factors influencing recurrence, and survival data in patients with 2023 International Federation of Gynecology and Obstetrics (FIGO) stage IIB endometrial cancer. Methods A retrospective analysis was conducted on patients with endometrial cancer who underwent surgery between 2005 and 2022 at seven different centers in Turkey. Demographic, clinicopathological, and survival data were collected and analyzed. Results Among 7323 patients, 565 (7.7%) were classified as 2023 FIGO stage IIB based on pathological results. Of 565 patients, 214 were followed without receiving adjuvant treatment, while 335 (95.4%) received adjuvant radiotherapy, and 16 (4.6%) received radiotherapy and chemotherapy. The locoregional recurrence rate was higher in patients with a tumor size >4 cm (p=0.038) and myometrial invasion >50% (p=0.045). In patients with distant metastasis, the recurrence rate was lower in those with myometrial invasion <50% compared with myometrial invasion ≥50% (p=0.031). The impact of adjuvant treatment on endometrial cancer patients revealed no significant differences for both disease free survival (p=0.85) and overall survival (p=0.54). Subgroup analyses showed that in patients with deep myometrial invasion, adjuvant treatment was associated with a significant increase in overall survival (p=0.044), but there was no effect on disease-free survival (p=0.12). Conclusions Patients with stage IIB endometrial cancer with myometrial invasion ≥50% were more likely to have locoregional and distant metastases. Adjuvant radiotherapy or chemoradiotherapy did not demonstrate an overall survival benefit in these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI